Ciltacabtagene Autoleucel (cilta-cel)

CARVYKTI™ (ciltacabtagene autoleucel) is a BCMA-directed, genetically modified autologous T-cell immunotherapy, which involves reprogramming a patient’s own T-cells with a transgene encoding a chimeric antigen receptor (CAR) that identifies and eliminates cells that express the B-cell maturation antigen (BCMA).